Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

Immunoglobulin G4-related disease affects approximately 20,000 people in the US

- PMLiVE

Novartis’ Vanrafia granted FDA approval for rare kidney disease IgA nephropathy

Almost 13 out of every million people in the US are diagnosed with IgAN each year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

The importance of the human touch in today’s AI world

The robots aren’t taking over – but they do have the potential to elevate our profession

- PMLiVE

Top-10 Best Practices for Virtual Publication Planning and Development

Virtual publication planning is rapidly evolving with new digital tools, but are you truly optimizing your strategy? Our article dives into the challenges of this new landscape, from data security...

Impetus Digital

- PMLiVE

Medscape at ESCMID 2025: Advancing Infectious Disease Education

Medscape, a global leader in infectious disease education, continues its commitment to advancing knowledge in the field. With 1.47 million ID learners in 2024, the Medscape team will travel to...

Medscape Education

EU flag

Genmab announces EC approval of Tivdak in recurrent or metastatic cervical cancer

Approximately 660,000 new cases of the disease were diagnosed globally in 2022 alone

- PMLiVE

Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

Around 800 people in the UK are diagnosed with late-stage disease every year

- PMLiVE

Pfizer and Flagship Pioneering enter autoimmune disease partnership

More than 100 known types of autoimmune diseases affect over 50 million people in the US

- PMLiVE

Life sciences in Europe – the top 20 global cities

The Global Cities Comparison Report benchmarked 20 global cities across five key areas

- PMLiVE

BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer

Up to 55% of non-metastatic NSCLC patients will develop disease recurrence despite surgical resection

- PMLiVE

BeiGene’s Tevimbra recommended by CHMP to treat small cell lung cancer

The aggressive form of lung cancer accounts for around 15% of all cases of the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links